A diverse pipeline of potential therapies for DKD exists, including incretin agonists, endothelin receptor antagonists, aldosterone synthase inhibitors, soluble guanylate cyclase stimulators and agents that target inflammatory pathways such as Janus kinase/Janus kinase 2 inhibitors and IL-6 monoclonal antibodies
5 However, the awareness of available therapeutic options remains low, prompting us to provide insights into these options through this article
Baseline estimated renal function was normal (eGFR 90 mL/min/1.73m2) in 57.2%, mildly impaired (eGFR 60 to 90 mL/min/1.73m2) in 35.9% and moderately impaired (eGFR 30 to 60 mL/min/1.73m2) in 6.9% of patients
As the authors explain, because their institution specialises in eye conditions, they are more likely to see higher numbers of NAION cases
Reduced portability requirements allow for designs that are more engaging, supportive and ergonomic, with more premium aesthetics driven by a consumer health mindset